Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11667126 | 0.83 | IDO1 (0.33) | EPHX1EPHX2NPC1MAPTMEN1 | |
| SCHEMBL11664814 | 0.83 | ALDH1A1 (0.32) | EPHX1EPHX2MAPTMEN1KMT2A | |
| SCHEMBL26028958 | 0.81 | RAPGEF4 (0.50) | NPC1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL9494328 | 0.81 | MEN1 (0.52) | NPC1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL5535465 | 0.77 | EPHX1 (0.47) | EPHX1EPHX2CA2CA4CA5A | |
| SCHEMBL2095962 | 0.77 | EPHX1 (0.52) | EPHX1EPHX2CA2CA4CA5A | |
| SCHEMBL8985134 | 0.74 | ALDH1A1 (0.32) | CA2MAPTALDH1A1 | |
| SCHEMBL2836022 | 0.73 | MAPT (0.44) | CA2NPC1MAPTMEN1KMT2A | |
| SCHEMBL8642760 | 0.73 | NPC1 (0.30) | NPC1MAPTRAB9AHTT | |
| SCHEMBL11262155 | 0.72 | MAPT (0.45) | EPHX1EPHX2CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2760856-A1 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049119-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2012149097-A2 | GUANIDYLIMIDAZOLE AND GUANIDYLIMIDAZOLINE DERIVATIVES AS ANTIMALARIAL AGENTS, SYNTHESIS OF AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF ARMY, (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149093-A1 | 2-GUANIDINO-4-OXO-IMIDAZOLINE DERIVATIVES AS ANTIMALARIAL AGENTS, SYNTHESIS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF ARMY (US) | 2012-11-01 | — | — | WO | disclosed |
| US-8283370-B2 | Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283370-B2 | Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110230533-A1 | IMIDAZOLIDINEDIONE DERIVATIVES AS ANTIMALARIAL AGENTS, PREPARATION THEREOF, AND METHODS OF USE | LIN AI JENG | 2011-09-22 | — | — | US | disclosed |
| US-20110230533-A1 | IMIDAZOLIDINEDIONE DERIVATIVES AS ANTIMALARIAL AGENTS, PREPARATION THEREOF, AND METHODS OF USE | LIN AI JENG | 2011-09-22 | — | — | US | disclosed |
| WO-2010051129-A2 | NEW IMIDAZOLIDINEDIONE DERIVATIVES AS ANTIMALARIAL AGENTS, PREPARATION THEREOF, AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2010-05-06 | — | — | WO | disclosed |
| US-4791229-A | WITH ACETIC ACID SOLVENT AND AUXILIARY BASE | BAYER AKTIENGESELLSCHAFT (DE) | 1988-12-13 | — | — | US | disclosed |
| EP-0220584-A2 | Process for the preparation of aryl cyanamides | BAYER AG (DE) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230533-A1 | IMIDAZOLIDINEDIONE DERIVATIVES AS ANTIMALARIAL AGENTS, PREPARATION THEREOF, AND METHODS OF USE | ITPA, EIF2AK2, ABL1 | EPHX1 2344/4885EPHX2 2813/4885CA2 2479/4885 |
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | EPHX1 2098/4885EPHX2 2196/4885CA2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.